Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | Systemic therapy for treating brain metastases

Rupert Bartsch • 5 May 2022
ESMO Breast 2022
Breast Cancer Antibodies Trastuzumab deruxtecan Tucatinib

Brain metastases are associated with high disease morbidity and mortality rates. Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, talks on systemic therapy for the treatment of brain metastases, which are now known to be effective, including tucatinib and trastuzumab deruxtecan. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Rupert Bartsch

2:09
The evolution of HER2 targeting in metastatic breast breast cancer
Rupert Bartsch • 7 Dec 2022
1:51
ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancer
Rupert Bartsch • 7 Dec 2022
0:53
ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer
Rupert Bartsch • 7 Dec 2022
0:31
Exciting developments in ADCs for BC presented at ESMO Breast 2022
Rupert Bartsch • 5 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals